Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a report released on Tuesday, MarketBeat Ratings reports. The brokerage set an “overweight” rating on the stock.

Separately, Wall Street Zen upgraded shares of Generate Biomedicines to a “hold” rating in a report on Saturday, March 14th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Generate Biomedicines has an average rating of “Buy” and an average target price of $25.00.

Generate Biomedicines Trading Down 1.7%

Shares of GENB opened at $11.83 on Tuesday. Generate Biomedicines has a 1 year low of $11.00 and a 1 year high of $15.32.

Generate Biomedicines News Summary

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: Piper Sandler initiated coverage with an “overweight” rating and a $24.00 price target (about 102.9% upside vs. the current $11.83). Article Title Zacks Article
• Positive Sentiment: Morgan Stanley started coverage with an “overweight” and a $20.00 price target (≈69% upside). Article Title TickerReport
• Positive Sentiment: Goldman Sachs initiated with a “buy” and $26.00 target (≈120% upside), another strong institutional vote of confidence. Article Title Zacks Article
• Positive Sentiment: Cantor Fitzgerald added coverage with an “overweight” view. Article Title Zacks Article
• Positive Sentiment: Guggenheim launched coverage with a “buy” and a $30.00 target (≈154% upside), the most aggressive target of the group. Article Title Zacks Article
• Neutral Sentiment: Short-interest reports published today are internally inconsistent (showing 0 shares and NaN days-to-cover), so there is no reliable evidence of significant short pressure based on the released data.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.